carvedilol has been researched along with Anoxemia in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate whether carvedilol influences exercise hyperventilation and the ventilatory response to hypoxia in heart failure (HF)." | 9.12 | Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia. ( Agostoni, P; Andreini, D; Apostolo, A; Bussotti, M; Cattadori, G; Contini, M; Magini, A; Palermo, P; Veglia, F, 2006) |
| "Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values." | 5.33 | Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. ( Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW, 2005) |
| "Exercise performance is better preserved with nebivolol than with carvedilol under acute exposure to HA hypoxia in healthy subjects." | 5.16 | Effects of beta-blockade on exercise performance at high altitude: a randomized, placebo-controlled trial comparing the efficacy of nebivolol versus carvedilol in healthy subjects. ( Agostoni, P; Bilo, G; Branzi, G; Caldara, G; Faini, A; Gregorini, F; Magrì, D; Malfatto, G; Parati, G; Parati, S; Revera, M; Savia, G; Styczkiewicz, K; Valentini, M, 2012) |
| "To evaluate whether carvedilol influences exercise hyperventilation and the ventilatory response to hypoxia in heart failure (HF)." | 5.12 | Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia. ( Agostoni, P; Andreini, D; Apostolo, A; Bussotti, M; Cattadori, G; Contini, M; Magini, A; Palermo, P; Veglia, F, 2006) |
| "Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values." | 1.33 | Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. ( Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamaura, S | 1 |
| Fukao, M | 1 |
| Ishida, K | 1 |
| Taguchi, M | 1 |
| Hashimoto, Y | 1 |
| Rea, G | 1 |
| Valente, T | 1 |
| de Rosa, N | 1 |
| Muto, M | 1 |
| Berritto, D | 1 |
| Bocchino, M | 1 |
| Diogo, LN | 1 |
| Pereira, SA | 1 |
| Nunes, AR | 1 |
| Afonso, RA | 1 |
| Santos, AI | 1 |
| Monteiro, EC | 1 |
| Bilo, G | 2 |
| Caldara, G | 2 |
| Styczkiewicz, K | 2 |
| Revera, M | 2 |
| Lombardi, C | 1 |
| Giglio, A | 1 |
| Zambon, A | 1 |
| Corrao, G | 1 |
| Faini, A | 2 |
| Valentini, M | 2 |
| Mancia, G | 1 |
| Parati, G | 2 |
| Karsten, M | 1 |
| Contini, M | 2 |
| Cefalù, C | 1 |
| Cattadori, G | 2 |
| Palermo, P | 2 |
| Apostolo, A | 2 |
| Bussotti, M | 2 |
| Magrì, D | 2 |
| Salvioni, E | 1 |
| Farina, S | 1 |
| Sciomer, S | 1 |
| Catai, AM | 1 |
| Agostoni, P | 3 |
| Savia, G | 1 |
| Parati, S | 1 |
| Gregorini, F | 1 |
| Branzi, G | 1 |
| Malfatto, G | 1 |
| Oliveira, PJ | 1 |
| Rolo, AP | 1 |
| Palmeira, CM | 1 |
| Moreno, AJ | 1 |
| Shyu, KG | 1 |
| Liou, JY | 1 |
| Wang, BW | 1 |
| Fang, WJ | 1 |
| Chang, H | 1 |
| Magini, A | 1 |
| Veglia, F | 1 |
| Andreini, D | 1 |
| Tual, L | 1 |
| Morel, OE | 1 |
| Favret, F | 1 |
| Fouillit, M | 1 |
| Guernier, C | 1 |
| Buvry, A | 1 |
| Germain, L | 1 |
| Dhonneur, G | 1 |
| Bernaudin, JF | 1 |
| Richalet, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cardiovascular and Metabolic Physiological Adaptations to Intermittent Hypoxia. Physiological Aspects and Expression of Receptors and Cellular Mediators[NCT02058823] | Phase 4 | 12 participants (Actual) | Interventional | 2013-08-07 | Terminated (stopped due to budget constraints) | ||
| HIGH Altitude CArdiovascular REsearch Latin America Population Study[NCT04751292] | 900 participants (Anticipated) | Observational | 2021-01-26 | Recruiting | |||
| Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function[NCT00517725] | Phase 4 | 60 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Comparison of the Cardiovascular, Metabolic and Respiratory Effects of Nebivolol and Carvedilol at High Altitude in Healthy Subjects.[NCT00924833] | Phase 4 | 27 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Difference in peak exercise minute ventilation between Time 1 and Time 3 (Time 3 - Time 1.~Minute ventilation = tidal volume (ml) multiplied by the respiratory rate (breaths/min)." (NCT00924833)
Timeframe: Time 1: sea level, baseline, no treatment. Time 3: within the first two days of high altitude exposure, under treatment.
| Intervention | L/min (Mean) |
|---|---|
| Placebo | 0.7 |
| Carvedilol | -9.3 |
| Nebivolol | 15.2 |
Difference in peak exercise oxygen consumption between Time 1 and Time 3 (Time 3 - Time 1) (NCT00924833)
Timeframe: Time 1: sea level, baseline, no treatment. Time 3: within the first two days of high altitude exposure, under treatment.
| Intervention | ml/Kg/min (Mean) |
|---|---|
| Placebo | -32.7 |
| Carvedilol | -37.6 |
| Nebivolol | -22.5 |
Minute ventilation at peak of exercise. Minute ventilation = tidal volume (ml) multiplied by the respiratory rate (breaths/min) (NCT00924833)
Timeframe: Time 1: sea level, baseline, no treatment. Time 2: sea level, after three weeks of allocated treatment. Time 3: within the first two days of high altitude exposure, under treatment.
| Intervention | L/min (Mean) | ||
|---|---|---|---|
| Time 1 | Time 2 | Time 3 | |
| Carvedilol | 90.3 | 89.6 | 84.5 |
| Nebivolol | 81.8 | 83.8 | 92.0 |
| Placebo | 93.9 | 95.6 | 90.3 |
Oxygen consumption at peak of exercise (NCT00924833)
Timeframe: Time 1: sea level, baseline, no treatment. Time 2: sea level, after three weeks of allocated treatment. Time 3: within the first two days of high altitude exposure, under treatment.
| Intervention | ml/Kg/min (Mean) | ||
|---|---|---|---|
| Time 1 | Time 2 | Time 3 | |
| Carvedilol | 37.6 | 36.2 | 24.0 |
| Nebivolol | 38.0 | 39.7 | 28.8 |
| Placebo | 33.9 | 33.9 | 22.9 |
4 trials available for carvedilol and Anoxemia
| Article | Year |
|---|---|
Effects of selective and nonselective beta-blockade on 24-h ambulatory blood pressure under hypobaric hypoxia at altitude.
Topics: Adrenergic beta-Antagonists; Adult; Altitude; Altitude Sickness; Benzopyrans; Blood Pressure; Carbaz | 2011 |
Effects of selective and nonselective beta-blockade on 24-h ambulatory blood pressure under hypobaric hypoxia at altitude.
Topics: Adrenergic beta-Antagonists; Adult; Altitude; Altitude Sickness; Benzopyrans; Blood Pressure; Carbaz | 2011 |
Effects of selective and nonselective beta-blockade on 24-h ambulatory blood pressure under hypobaric hypoxia at altitude.
Topics: Adrenergic beta-Antagonists; Adult; Altitude; Altitude Sickness; Benzopyrans; Blood Pressure; Carbaz | 2011 |
Effects of selective and nonselective beta-blockade on 24-h ambulatory blood pressure under hypobaric hypoxia at altitude.
Topics: Adrenergic beta-Antagonists; Adult; Altitude; Altitude Sickness; Benzopyrans; Blood Pressure; Carbaz | 2011 |
Effects of carvedilol on oxygen uptake and heart rate kinetics in patients with chronic heart failure at simulated altitude.
Topics: Adrenergic Antagonists; Aged; Altitude; Carbazoles; Carvedilol; Chronic Disease; Exercise Test; Fema | 2012 |
Effects of beta-blockade on exercise performance at high altitude: a randomized, placebo-controlled trial comparing the efficacy of nebivolol versus carvedilol in healthy subjects.
Topics: Adrenergic beta-Antagonists; Adult; Altitude; Benzopyrans; Carbazoles; Carvedilol; Double-Blind Meth | 2012 |
Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cross-Over Studies; Double-Blind Method; Echoca | 2006 |
6 other studies available for carvedilol and Anoxemia
| Article | Year |
|---|---|
Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats.
Topics: Adrenergic beta-Antagonists; Animals; Biotransformation; Carbazoles; Carvedilol; Chronic Disease; Di | 2014 |
Pulmonary capillary hemangiomatosis: a diagnostic challenge.
Topics: Carbazoles; Carvedilol; Delayed Diagnosis; Disease Progression; Furosemide; Granuloma, Pyogenic; Hum | 2015 |
Efficacy of carvedilol in reversing hypertension induced by chronic intermittent hypoxia in rats.
Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Chronic Disease; Hypertension; Hypoxia; Ma | 2015 |
Carvedilol reduces mitochondrial damage induced by hypoxanthine/xanthine oxidase: relevance to hypoxia/reoxygenation injury.
Topics: Adrenergic beta-Antagonists; Animals; Calcium; Carbazoles; Carvedilol; Cyclosporine; Hypoxanthine; H | 2001 |
Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
Topics: Acetylcysteine; Animals; Antihypertensive Agents; Aorta; Arteries; Blotting, Western; Body Weight; C | 2005 |
Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Hypertrop | 2006 |